234 related articles for article (PubMed ID: 22201704)
1. Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
Yi T; Elson P; Mitsuhashi M; Jacobs B; Hollovary E; Budd GT; Spiro T; Triozzi P; Borden EC
Oncotarget; 2011 Dec; 2(12):1155-1164. PubMed ID: 22201704
[TBL] [Abstract][Full Text] [Related]
2. Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/interleukin-2 and mediates its antitumor activity in vivo.
Fan K; Borden E; Yi T
J Interferon Cytokine Res; 2009 Aug; 29(8):451-60. PubMed ID: 19514839
[TBL] [Abstract][Full Text] [Related]
3. Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
Fan K; Zhou M; Pathak MK; Lindner DJ; Altuntas CZ; Tuohy VK; Borden EC; Yi T
J Immunol; 2005 Nov; 175(10):7003-8. PubMed ID: 16272361
[TBL] [Abstract][Full Text] [Related]
4. Anticancer activity of sodium stibogluconate in synergy with IFNs.
Yi T; Pathak MK; Lindner DJ; Ketterer ME; Farver C; Borden EC
J Immunol; 2002 Nov; 169(10):5978-85. PubMed ID: 12421984
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Agarwala SS; Kirkwood JM
Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
[TBL] [Abstract][Full Text] [Related]
6. Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents.
Kundu S; Fan K; Cao M; Lindner DJ; Zhao ZJ; Borden E; Yi T
J Immunol; 2010 Jun; 184(11):6529-36. PubMed ID: 20421638
[TBL] [Abstract][Full Text] [Related]
7. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines.
Pathak MK; Yi T
J Immunol; 2001 Sep; 167(6):3391-7. PubMed ID: 11544330
[TBL] [Abstract][Full Text] [Related]
8. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N
Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197
[TBL] [Abstract][Full Text] [Related]
9. Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors.
Naing A; Reuben JM; Camacho LH; Gao H; Lee BN; Cohen EN; Verschraegen C; Stephen S; Aaron J; Hong D; Wheler J; Kurzrock R
J Cancer; 2011 Feb; 2():81-9. PubMed ID: 21326629
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.
Egberts F; Gutzmer R; Ugurel S; Becker JC; Trefzer U; Degen A; Schenck F; Frey L; Wilhelm T; Hassel JC; Schadendorf D; Livingstone E; Mauch C; Garbe C; Berking C; Rass K; Mohr P; Kaehler KC; Weichenthal M; Hauschild A
Ann Oncol; 2011 Jul; 22(7):1667-1674. PubMed ID: 21220519
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action.
Li J; Lindner DJ; Farver C; Borden EC; Yi T
Cancer Chemother Pharmacol; 2007 Aug; 60(3):341-9. PubMed ID: 17103170
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma.
Bajetta E; Del Vecchio M; Nova P; Fusi A; Daponte A; Sertoli MR; Queirolo P; Taveggia P; Bernengo MG; Legha SS; Formisano B; Cascinelli N
Ann Oncol; 2006 Apr; 17(4):571-7. PubMed ID: 16469753
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.
Kim KB; Legha SS; Gonzalez R; Anderson CM; Johnson MM; Liu P; Papadopoulos NE; Eton O; Plager C; Buzaid AC; Prieto VG; Hwu WJ; Frost AM; Alvarado G; Hwu P; Ross MI; Gershenwald JE; Lee JE; Mansfield PF; Benjamin RS; Bedikian AY
Melanoma Res; 2009 Feb; 19(1):42-9. PubMed ID: 19430405
[TBL] [Abstract][Full Text] [Related]
14. Impact of Interferon-alpha1b (IFN-α1b) on Antitumor Immune Response: An Interpretation of the Promising Therapeutic Effect of IFN-alpha1b on Melanoma.
Liu Y; Ma J; Yang Y; Liu L; Zhu G; Wang X; Wang S; Guo W; Yue Q; Zhao T; Li C; Gao T; Shi Q
Med Sci Monit; 2020 Mar; 26():e922790. PubMed ID: 32210221
[TBL] [Abstract][Full Text] [Related]
15. Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma.
Daponte A; Signoriello S; Maiorino L; Massidda B; Simeone E; Grimaldi AM; Caracò C; Palmieri G; Cossu A; Botti G; Petrillo A; Lastoria S; Cavalcanti E; Aprea P; Mozzillo N; Gallo C; Comella G; Ascierto PA;
J Transl Med; 2013 Feb; 11():38. PubMed ID: 23402397
[TBL] [Abstract][Full Text] [Related]
16. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
Musa A; Khalil E; Hailu A; Olobo J; Balasegaram M; Omollo R; Edwards T; Rashid J; Mbui J; Musa B; Abuzaid AA; Ahmed O; Fadlalla A; El-Hassan A; Mueller M; Mucee G; Njoroge S; Manduku V; Mutuma G; Apadet L; Lodenyo H; Mutea D; Kirigi G; Yifru S; Mengistu G; Hurissa Z; Hailu W; Weldegebreal T; Tafes H; Mekonnen Y; Makonnen E; Ndegwa S; Sagaki P; Kimutai R; Kesusu J; Owiti R; Ellis S; Wasunna M
PLoS Negl Trop Dis; 2012; 6(6):e1674. PubMed ID: 22724029
[TBL] [Abstract][Full Text] [Related]
17. Short communication: phase I clinical and gene modulatory evaluation of tamoxifen and IFN-alpha2b.
Thakkar SG; Peereboom D; Olencki T; Jacobs B; Elson P; Rybicki L; Lindner DJ; Borden EC
J Interferon Cytokine Res; 2006 Nov; 26(11):800-3. PubMed ID: 17115898
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide and cisplatin in avdanced malignant melanoma.
Daponte A; Ascierto PA; Gravina A; Melucci M; Scala S; Ottaiano A; Simeone E; Palmieris G; Comella G
Anticancer Res; 2005; 25(2B):1441-7. PubMed ID: 15865103
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.
Varker KA; Biber JE; Kefauver C; Jensen R; Lehman A; Young D; Wu H; Lesinski GB; Kendra K; Chen HX; Walker MJ; Carson WE
Ann Surg Oncol; 2007 Aug; 14(8):2367-76. PubMed ID: 17534686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
